<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05103423</url>
  </required_header>
  <id_info>
    <org_study_id>STS-BDB001-06</org_study_id>
    <nct_id>NCT05103423</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of BDB-001 Injection in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)</brief_title>
  <official_title>A Multicenter, Randomized, Double-blind, Placebo Parallel-controlled, Phase I/II Study to Explore Safety and Efficacy of BDB-001 Injection in Subjects With Moderate to Severe Hidradenitis Suppurativa</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Staidson (Beijing) Biopharmaceuticals Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing Defengrui Biotechnology Co. Ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Staidson (Beijing) Biopharmaceuticals Co., Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to explore the safety and efficacy of treatment with BDB-001 Injection in adults with&#xD;
      moderate to severe hidradenitis suppurativa (HS).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 24, 2021</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v5.0.</measure>
    <time_frame>Week 8</time_frame>
    <description>Safety and tolerability of BDB-001 injection after multiple administration in the treatment of HS patients.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants developing anti-BDB-001 antibodies.</measure>
    <time_frame>Week 8</time_frame>
    <description>Safety and tolerability of BDB-001 injection after multiple administration in the treatment of HS patients.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC) of BDB-001 Assessment of pharmacokinetic parameters.</measure>
    <time_frame>Week 8</time_frame>
    <description>To evaluate the pharmacokinetic characteristics of BDB-001 injection after multiple administration in HS patients.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak Plasma Concentration (Cmax) of BDB-001and time to reach Cmax Assessment of pharmacokinetic parameters.</measure>
    <time_frame>Week 8</time_frame>
    <description>To evaluate the pharmacokinetic characteristics of BDB-001 injection after multiple administration in HS patients.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Minimal Plasma Concentration (Cmin) of BDB-001 Assessment of pharmacokinetic parameters.</measure>
    <time_frame>Week 8</time_frame>
    <description>To evaluate the pharmacokinetic characteristics of BDB-001 injection after multiple administration in HS patients.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal phase half-life Assessment of pharmacokinetic parameters.</measure>
    <time_frame>Week 8</time_frame>
    <description>To evaluate the pharmacokinetic characteristics of BDB-001 injection after multiple administration in HS patients.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in INAPP (Inflammatory Nodules, Abscesses,Pyorrhea, Pain VAS) score from Day 0 by time point</measure>
    <time_frame>From Day 0 until Day 56</time_frame>
    <description>INAPP Score=(Inflammatory Nodule Count) + (Abscess Count*2) + (Pyorrhea *2)+（Pain VAS）.The higher the score the more severe is the disease/worse is the outcome.&#xD;
Pain VAS：This is a segmented numeric version of the visual analog scale in which a respondent selects a whole number (0-10) that best reflects the intensity of their pain. The scale title for the VAS is points. The minimum score is 0 points (No skin pain), and the maximum score is 10 points (Skin pain as bad as you can imagine). The higher the score the more severe is the disease/worse is the outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in International Hidradenitis Suppurativa Severity Score System (IHS4) score from Day 0 by time point</measure>
    <time_frame>From Day 0 until Day 56</time_frame>
    <description>The International Hidradenitis Suppurativa Severity Score 4 (IHS4: developed by the European Hidradenitis Suppurativa Foundation Investigator Group)，IHS4 Score=(Nodule Count) + (Abscess Count*2) + (Draining Tunnel Count *4).&#xD;
IHS4 score uses a range grades:&#xD;
Mild= 0-3; Moderate=4-10; Severe ≥11.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in modified Sartorius Score (mSS) from Day 0 by time point</measure>
    <time_frame>From Day 0 until Day 56</time_frame>
    <description>The mSS is a summation of HS lesions based on a number of factors including anatomical region, number and type of lesions, distance between relevant lesions and lesions clearly separated by normal skin in each region measured as HS clinical parameters. The scale title for mSS is points. The mSS has a minimum value of 0 and no upper limit. The higher the score the more severe is the disease/worse is the outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Hidradenitis Suppurativa Clinical Response (HiSCR) from Day 0 by time point</measure>
    <time_frame>From Day 0 until Day 56</time_frame>
    <description>The definition for response to treatment based on HiSCR relative to Baseline was: at least 50% reduction in abscesses and inflammatory nodule (AN) count (over all anatomical regions) with no increase in number of abscesses and in number of draining fistulas.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Hidradenitis suppurativa-Physician Global Assessment (HS-PGA) score from Day 0 by time point</measure>
    <time_frame>From Day 0 until Day 56</time_frame>
    <description>Hidradenitis Suppurativa - Physician's Global Assessment (HS-PGA)classifies patients' severity into six categories:clear, minimal, mild, moderate, severe, and very severe, based on the number and quality of inflammatory lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Dermatology Life Quality Index (DLQI) score from Day 0 by time point</measure>
    <time_frame>From Day 0 until Day 56</time_frame>
    <description>A score is documented for each of the 10 DLQI items, ranging from 0 to 3 for each item. The scale title for DLQI is points. The total score is the sum of the responses to all 10 DLQI items, ranging from the minimum of 0 points to the maximum of 30 points. A higher score corresponds to worse health related quality of life/outcome.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Hidradenitis Suppurativa</condition>
  <arm_group>
    <arm_group_label>Treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BDB-001 Injection</intervention_name>
    <description>Single IV infusions of BDB-001 Injection diluted in sodium chloride</description>
    <arm_group_label>Treatment group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Single IV infusions of Placebo Injection diluted in sodium chloride</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 years old≤Age≤65 years old, male or female;&#xD;
&#xD;
          -  Diagnosis of HS for at least 6 months;&#xD;
&#xD;
          -  HS lesions must be present in at least two distinct anatomical areas, one of which&#xD;
             must be at least located in the apocrine sweat gland area and Hurley Stage II or&#xD;
             Hurley Stage III;&#xD;
&#xD;
          -  Total abscess and inflammatory nodule (AN) count of ≥ 3.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject was previously treated with adalimumab or another biologic product during the&#xD;
             3 months before the first administration;&#xD;
&#xD;
          -  Subject received any oral antibiotic treatment for HS within 2 weeks before the first&#xD;
             administration;&#xD;
&#xD;
          -  Subject received any oral retinoids treatment for HS within 4 weeks before the first&#xD;
             administration;&#xD;
&#xD;
          -  Subject received oral opioids analgesics within 1 week before the first&#xD;
             administration;&#xD;
&#xD;
          -  Systematic treatment with glucocorticoid or intramural injection within 4 weeks before&#xD;
             the first administration;&#xD;
&#xD;
          -  History of heart disease or malignancy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Du Zhouqi</last_name>
    <phone>+86 17600505723</phone>
    <email>duzhouqi@staidson.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking University First Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100034</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Li Hang</last_name>
      <phone>+86 13693058190</phone>
      <email>drlihang@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Plastic Surgery Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100144</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wang Baoxi</last_name>
      <phone>+86 13911001336</phone>
      <email>wangbx@vip.126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jin Hongzhong</last_name>
      <phone>+86 13693583080</phone>
      <email>jinhongzhong@263.net</email>
    </contact>
    <contact_backup>
      <last_name>Chen Rui</last_name>
      <phone>+86 13811790704</phone>
      <email>chenrui04@126.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Xiangya Hospital, Central South University</name>
      <address>
        <city>Hunan</city>
        <state>Changsha</state>
        <zip>410008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Li Ji</last_name>
      <phone>+86 15674924749</phone>
      <email>993161577@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>West China Hospital of Sichuan University</name>
      <address>
        <city>Sichuan</city>
        <state>Chengdu</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiang Xian</last_name>
      <phone>+86 18980601693</phone>
      <email>jennyxianj@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Third Affiliated Hospital of Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>51063</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lai Wei</last_name>
      <phone>+86 18922102962</phone>
      <email>drlaiwei@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chinese Academy of Medical Sciences and Peking Union Medical College</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210042</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Li Min</last_name>
      <phone>+86 15951862791</phone>
      <email>drlimin@sina.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Qilu Hospital of Shandong University</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250012</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sun Qing</last_name>
      <phone>+86 18560082626</phone>
      <email>sunqing7226@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Huashan Hospital of Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200040</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xu Jinhua</last_name>
      <phone>+86 13818978539</phone>
      <email>xjhhsyy@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Xi'an Jiaotong University</name>
      <address>
        <city>Xian</city>
        <state>Shanxi</state>
        <zip>710004</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Geng Songmei</last_name>
      <phone>+86 13060423612</phone>
      <email>gsm312@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 23, 2021</study_first_submitted>
  <study_first_submitted_qc>November 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 2, 2021</study_first_posted>
  <last_update_submitted>November 1, 2021</last_update_submitted>
  <last_update_submitted_qc>November 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hidradenitis Suppurativa</mesh_term>
    <mesh_term>Hidradenitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

